Nigel Courtenay-Luck

The Nucleolin Targeting Aptamer AS1411 Destabilizes <i>Bcl-2</i> Messenger RNA in Human Breast Cancer Cells

Sridharan Soundararajan, Weiwei Chen, Eleanor K. Spicer et al. · Cancer Research · 2008 · 510 citations

Life Sciences, Molecular Biology, Oncology +14

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Harriet S. Walter, Simon A. Rule, Martin J.S. Dyer et al. · Blood · 2015 · 265 citations · Full text

Medicine, Oncology, Pharmacology +12

Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells

Sridharan Soundararajan, Li Wang, Vijayalakshmi Sridharan et al. · Molecular Pharmacology · 2009 · 237 citations · Full text

Medicine, Molecular Biology, Oncology +13

Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms.

Nigel Courtenay-Luck, Agamemnon A. Epenetos, Richard E. Moore et al. · PubMed · 1986 · 209 citations

Pharmacy, Immunology, Oncology +17

Cyclic AMP: a mitogenic signal for Swiss 3T3 cells.

Enrique Rozengurt, Alex Legg, George Strang et al. · Proceedings of the National Academy of Sciences · 1981 · 150 citations · Full text

Life Sciences, Biochemistry, Pharmacology +13